Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pan-tumor × Oxaliplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 190 Stomach Neoplasms 154 Rectal Neoplasms 132 Colonic Neoplasms 73 Pancreatic Neoplasms 70 Neoplasm Metastasis 58 Esophageal Neoplasms 51 Neoplasms 27 Adenocarcinoma Of Esophagus 27 Adenocarcinoma 26 Cholangiocarcinoma 24 Carcinoma, Hepatocellular 24 Biliary Tract Neoplasms 20 Lymphoma, Large B-Cell, Diffuse 17 Recurrence 16 Carcinoma, Non-Small-Cell Lung 14 Breast Neoplasms 13 Liver Neoplasms 10 Gallbladder Neoplasms 10 Gastrointestinal Neoplasms 9 Locally Advanced Rectal Cancer 8 Head and Neck Neoplasms 8 Esophageal Squamous Cell Carcinoma 8 Peritoneal Neoplasms 7 Ovarian Neoplasms 7 Colorectal Cancer Metastatic 6 Bile Duct Neoplasms 6 Carcinoma 5 Advanced Gastric Cancer 5 Urinary Bladder Neoplasms 4

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡